Logotype for PeptiDream Inc

PeptiDream (4587) Q4 2023 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for PeptiDream Inc

Q4 2023 earnings summary

1 Nov, 2026

Executive summary

  • FY2023 revenue rose 6.9% to ¥28,712M; core operating profit fell 25.6% to ¥7,166M and profit attributable to owners fell 59.8% to ¥3,036M.

  • Radiopharmaceutical growth offset lower Drug Discovery and Development revenue; core operating profit, operating profit and net income exceeded forecasts.

Financial highlights

  • Revenue was ¥28,712M; gross profit was ¥17,219M versus ¥18,113M in FY2022.

  • Core operating profit was ¥7,166M and IFRS operating profit ¥6,773M; operating profit declined 24.6% YoY.

  • Profit before tax fell 34.6% to ¥4,353M; profit attributable to owners fell 59.8% to ¥3,036M, and basic EPS was ¥23.41 versus ¥58.19.

  • Comprehensive income reached ¥8,761M, including ¥5,741M in gains on financial assets at fair value through OCI, including increased RayzeBio share value after BMS’s tender offer announcement.

Outlook and guidance

  • FY2024 forecast: revenue ¥35,000M, core operating profit ¥10,900M, operating profit ¥10,500M, pretax profit ¥10,200M and parent-attributable profit ¥7,300M.

  • Growth priorities include marketed products and Alzheimer’s PET imaging, plus RI-PDC program progress and clinical-stage pipeline expansion.

  • Medium- to long-term revenue targets are ¥35B within ~3 years and ¥50B–¥100B over 5–7 years through a platform-plus-portfolio model.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from PeptiDream